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Abstract Characterization of autoantibodies specific for
some disease-related proteins, would allow to better assess
their role as diagnostic and prognostic markers. In the light
of increasing evidence for both humoral and cellular
adaptive immune responses in the pathophysiology of
Alzheimer’s disease (AD), and data on the increased small
heat-shock proteins (sHSP) expression in this disease, it
seemed justified to assess humoral response against sHSP
in AD patients. The aim of the study was to check whether
AD has the ability to elicit immune response against small
HSP, which could also serve as disease biomarkers. IgG
and IgM autoantibodies against alpha B-crystallin and anti-
HSP 60 IgG autoantibodies were assessed in 59 AD
patients and 59 healthy subjects. Both IgM and IgG
autoantibodies against alpha B-crystallin in AD patients
were significantly higher compared to healthy controls
(p\ 0.05). No statistically significant differences were
found between AD patients and healthy subjects were
found in anti-HSP60 IgG autoantibody titers (p = 0.29).
Anti-HSP60 antibodies present in AD patients may indeed
belong to natural human immune repertoire, and chronic
neurodegenerative process does not have significant
inducing effect on the systemic immunoreactivity against
HSP60. Increased titers of IgM and IgG autoantibodies
against alpha B-crystallin in AD patients may reflect acti-
vation of humoral immune response in the course of this
chronic disease, probably secondary to its increased
expression. Further prospective studies, on larger group of
AD patients and measuring a change in antibodies titers
with disease progression are necessary to assess the exact
role of these antibodies in AD.
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Introduction
Identification of disease-specific diagnostic and prognostic
biomarkers which would allow for an early detection and
clinical follow-up of Alzheimer’s disease (AD) patients is
very important. As there is increasing evidence for both
humoral and cellular adaptive immune responses in the
pathophysiology of AD, assessment of disease-related B
and T cell responses may constitute a promising source of
potential early biomarkers specific for certain disorders.
Characterization of autoantibodies specific for some dis-
ease-related proteins, would allow to better decipher their
role as early diagnostic and prognostic markers in AD. In
the light of previously emerging hypotheses on the acti-
vation of the adaptive immune system against amyloid b
(Ab) aiming to decrease the accumulation of this peptide in
the brain (Solomon et al. 1997; Schenk et al. 1999), it
seemed justified to assess humoral response against other
peptides which are overexpressed in AD.
Heat-shock proteins (HSPs) are functionally and
immunologically highly conserved molecules present in
almost all living organisms (Ellis 2007). HSPs are up-
regulated in response to cellular stress to protect the cell
from a variety of stresses (Kelly and Yenari 2002). This
increased HSP expression takes place in cells exposed to
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mild stress and protects them against subsequent stress.
However, in cells subjected to severe stress, HSP promote
apoptosis.
In AD, HSPs expression is associated with deposition of
Ab and neurofibrillary tangles, and recent findings suggest
that HSPs prevent the accumulation of Ab (Abdul et al.
2006; Evans et al. 2006; Shimura et al. 2004).
In the light of evidence for increased expression of some
HSPs in brain tissues in patients with AD (Bjo¨rkdahl et al.
2008) and also in brains of patients with mild cognitive
impairment (MCI) (Di Domenico et al. 2010), we decided
to assess humoral response against sHSP in AD, and to
look for potential biomarkers of the disease.
To test this hypothesis, we assessed the presence of
autoantibodies against small HSP, like alpha B-crystallin
and HSP 60 in sera of patients suffering from AD. We
assessed all measurements from AD patients in relation to
autoantibody levels in healthy control subjects.
Alpha B-crystallin
Alpha B-crystallin is a small heat-shock protein (sHSP),
which occurs at increased levels in brains of Alzheimer’s
disease patients, and co-localizes with amyloid b (Ab)
(Renkawek et al. 1994). AD pathology involves not only
aggregation of abnormal proteins, but also their decreased
degradation, and cytoskeletal disruption. Small HSPs take
part in protein degradation and protection against protein
aggregation, and they interact with several cytoskeletal
components such as microtubules (MT) and neurofilaments
(NF). There is evidence that some small heat-shock proteins
(sHSPs), like Hsp27 and alpha B-crystallin, are up-regulated
in AD, especially in the regions commonly affected by AD
but its consequences are still largely unknown (Bjo¨rkdahl
et al. 2008; Mao et al. 2001). The presence and increased
sHsps expression in AD brains may indeed reflect a defen-
sive response to prevent amyloid fibril formation and its
toxicity (Renkawek and Bosman 1995).
HSP 60 and related autoantibodies
Anti-60 kD heat-shock protein (Hsp60) antibodies are pre-
sent in sera of healthy human subjects (Varbiro et al. 2010),
also in sera of patients with inflammatory and autoimmune
disorders (Yokota and Fujii 2010; Mayr et al. 1999). In the
light of evidence for inflammatory process present in human
brains of patients with AD, as well as data on increased
expression of different sHSP in neurodegenerative disorders,
it may be hypothesized that AD may be also accompanied
by the presence of anti-HSP antibodies.
Thus, we decided to assess the humoral response against
sHSP in sera of AD patients in comparison to healthy
controls, to assess the presence of adaptive immune response
in AD and to look for early biomarkers of the disease.
Materials and methods
59 AD patients in different clinical stages of the disease [on
Clinical Dementia Rating (CDR) grade 0.5–3] treated in
the Department of Neurology of Medical University of
Lublin, Poland were enrolled. All AD patients fulfilled
NINCDS–ADRDA criteria for probable Alzheimer’s dis-
ease diagnosis (McKhann et al. 1984). AD patients were
divided into three subgroups: mild AD (CDR 0.5–1),
moderate (CDR 2) and severe (CDR 3).
Serum samples from all 59 AD patients were examined
for the presence of IgG and IgM autoantibodies against
alpha B-crystallin and IgG antibodies against HSP 60. In
addition, serum samples from 59 healthy controls matched
for age and gender were assessed for the same antibodies.
IgG and IgM autoantibodies against alpha B-crystallin
were measured by a commercially available ELISA system
according to the instructions of the manufacturer (Mediag-
nost,Germany).All analysiswereperformed in duplicate.The
ELISA (E100) uses an internal standard pool serum for cal-
culation of antibody titers and employing microplates coated
with myelin-specific proteins purified from bovine brain. The
autoantibody titer was calculated after the subtraction of
nonspecific binding and blanks. The titers were estimated on
the base of calibration curve of autoantibody standards and
expressed in Mediagnost Units per milliliter (MU/mL).
For measurement of anti-HSP 60 antibodies we used
enzyme-linked immunosorbent assay, which is a validated
method (ADI-EKS-650, Enzo Life Sciences). Concentra-
tion values were expressed in ng/mL. Assay Designs Anti-
Human Hsp60 (total) ELISA Kit uses recombinant human
Hsp60 bound to the wells of the immunoassay plate to bind
anti-human Hsp60 antibodies present in human serum.
Blood samples were collected between 8:00 and 10:00
a.m., transferred to the lab on ice, centrifuged and serum
was stored at -70 C within 60 min thereafter. The study
was approved by the local Ethics Committee of Medical
University of Lublin, Poland, and all study participants
gave written informed consent for study participation.
Statistical analysis
Antibodies titer differences between study group and the
control subjects were estimated with the usage of ANOVA
test. For AD subgroups analysis Kruskal–Wallis and
U Mann–Whitney tests were applied. p value\0.05 was
considered statistically significant (two sided). Statistical
calculations were done with the usage of InStat GraphPad
Software Inc, CA.
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Results
Antibodies against alpha B-crystallin
We confirmed the presence of IgM and IgG autoantibodies
against alpha B-crystallin in investigated groups of AD
patients and healthy subjects, and observed statistically
significant higher levels of both IgG (p\ 0.05) and IgM
autoantibodies (p\ 0.05) titers in AD patients compared to
healthy control subjects. In AD subgroup analysis, we have
found statistically significant higher levels of IgG antibodies
titers in patients with severe AD, as compared to patients
with mild disease severity (p = 0.003). In comparison of
AD subgroups with very mild and mild dementia (CDR
0.5–1.0) versus moderate and severe (CDR 2–3), we also
confirmed significantly higher IgGs antibodies titers for
more advanced AD patients (p = 0.03). No differences were
observed in IgM titers among subgroups of AD patients.
Anti-HSP60 autoantibodies
We have not observed statistically significant differences in
levels of anti-HSP 60 IgG autoantibodies between AD
patients and healthy controls (p[ 0.05). Also in the AD
subgroup analysis we have not found statistically signifi-
cant differences in the anti HSP60 antibodies titers between
investigated subgroups.
Demographical, clinical and biochemical characteristics
of the study population are shown in Tables 1, 2 and 3.
Discussion
Autoantibodies against alpha B-crystallin
Here we provided evidence for the presence of humoral
response against sHSPs in AD. Alpha B-crystallin sup-
presses the aggregation and precipitation of a wide range of
proteins, including formation of amyloid fibrils in AD.
Data on the increased expression of sHSP in Alzheimer’s
disease have been confirmed in many studies (Bjo¨rkdahl
et al. 2008; Renkawek et al. 1994; Shinohara et al. 1993).
Higher IgG and IgM antibodies titers against alpha
B-crystallin in AD patients, confirmed in this study, may
reflect the increasing role of this protein in prevention of
Ab fibril formation in the course of neurodegenerative
process, and is probably secondary to increased expression
of this protein. This hypothesis may be additionally sup-
ported by the increase of the IgG antibodies titers with
more advanced neurodegenerative process, which we
confirmed in the study.
However, it is not completely clear whether found
antibodies against sHSP reflect diffuse CNS injury or
contribute to this injury. Monahan et al. (2008) presented
the model on how the immune adaptive response may be
involved in the pathogenesis and progression of neurode-
generative disorders. Progressive neurodegenerative disor-
der is accompanied by death of the CNS cells and
presentation of their new antigens to the immune system,
with subsequent activation of T and B cells. B cells or
specific autoantibodies may then enter the CNS across
dysfunctional blood–brain barrier (BBB), produce cytoki-
nes which activate microglia, and release autoantibodies.
This may lead to further inflammation and subsequent
cellular death (Monahan et al. 2008). Recent data suggest
blood–brain barrier dysfunction in the course of neurode-
generative process (Carvey et al. 2009; Viggars et al. 2011;
Simpson et al. 2010).
It should be mentioned here, however, that there is
evidence on the role of alpha B-crystallin, not as a target
for the autoimmune response, but rather as a chaperone,
which helps to bind different antibodies irrespective of
their specificity (Rothbard et al. 2001). Rothbard et al.
(2001) in their study, performed on multiple sclerosis (MS)
patients, showed that small HSPs (like alpha B-crystallin)
bind different immunoglobulins (Igs) with high affinity,
and in fact are receptors of the Igs, not the antigens for
them. This would mean that alpha B-crystallin does not
elicit itself specific immune response (Rothbard et al.
2001). Comparable immunoreactivity to alpha B-crystallin
of sera of MS patients and healthy controls was previously
described by van Noort (2006). For this reason, the
assessment of humoral response in different inflammatory
disorders may be difficult, as majority of immunoassays are
Table 1 Demographic and
clinical data of the study
population
Demographic characteristic of study group Alzheimer’s disease patients Control subjects
Subjects (female/male) 59 (26/33) 59 (29/30)
Age (years) ± SD (range) 72.93 ± 7.36 (55–84) 72.58 ± 5.86 (58–82)
Disease duration (years) ± SD (range) 7.65 ± 2.69 (4–13) NA
MMSE (0–30) ± SD (range) 16.86 ± 4.45 (9–24) 28.54 ± 1.07 (27–30)
CDR ± SD (range) 2.16 ± 0.74 (0.5–3) NA
Data are presented as means with standard deviation (SD)
MMSE mini mental state examination, CDR clinical dementia rating, NA not applicable
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based on typical antibody–antigen interaction, and they do
not consider the possibility of the antigen binding the
antibody, and this can be also the limitation of our study.
Whether results presented by Rothbard (2001) are disease
specific or can be adopted to different other inflammatory
disorders, requires further investigations. Contrary to their
study, we observed significantly higher immunoreactivity
to alpha B-crystallin in sera of AD patients compared to
healthy subjects.
Autoantibodies against HSP 60
The study confirmed the presence of anti-HSP 60 autoan-
tibodies in sera of AD patients and healthy subjects,
without statistically significant differences between inves-
tigated subgroups. AD patients presented, however,
slightly increased antibodies titers compared to healthy
subjects. This is interesting in the light of our recent study
(Papuc´ et al. 2015), where we confirmed significantly
increased anti-HSP 60 autoantibodies titers in another
neurodegenerative disorder, Parkinson’s disease.
There is evidence that in AD both peripheral and brain
endogenous inflammatory processes enhance the disease
progression (Monsonego et al. 2013). Additionally, a
growing body of evidence demonstrates that Ab plaques
induce an inflammatory reaction in the brain (McGeer et al.
2005; Vom Berg et al. 2012). Recent studies demonstrated
the significant pathological effect of Ab on cerebral amy-
loid angiopathy that causes vascular inflammation, brain
hemorrhages, compromised perivascular drainage and
altered blood flow (Meyer et al. 2008; Thal et al. 2008).
Inflammatory processes such as microglia, astrocytes
and complement activation, cytokine elevation and acute
phase protein changes are thought to represent, at least
partially, a response to the accumulation of Ab in the
vasculature and parenchyma of the brain. A compromised
immune system may have substantial impact on these
processes and lead to neuronal repair processes, which
enhance the progression of AD.
We hypothesized that in the light of evidence for
increased expression of sHSP in different neurodegenera-
tive disorders (Bjo¨rkdahl et al. 2008), and evidence of
activation of humoral immunoreactivity to other protein
depositions, like Ab (Monsonego et al. 2013), one can
expect activation of humoral response against this HSP60,
as we previously confirmed for Parkinson’s disease (Papuc´
et al. 2015). In this study, we confirmed comparable
immunoreactivity against HSP 60 in AD and healthy sub-
jects, with no influence of AD progression on anti-HSP60
antibodies titers.
The presence of anti-HSP 60 autoantibodies is healthy
people and in different disorders is still unclear. They could
be cross-reacting antibodies induced by bacterial infections
(Mayr et al. 1999) or real autoantibodies (Cohen and
Young 1991). Numerous data support that the carriage of
anti-Hsp60 autoantibodies may be a part of natural anti-
body repertoire, which can be an inherited trait, and the
cumulative antibody-inducing effects of multiple infections
add to this trait (Varbiro et al. 2010; Zlacka et al. 2006).
Natural antibodies refer to antibodies that are present in the
serum of healthy individuals without overt immunization
or infection (Coutinho et al. 1995). Thus, the presence of
anti-self Hsp autoantibodies may be an integral part of the
normal immune function, playing role in self-protection
and regulation of autoimmunity. In humans natural
autoantibodies may belong to IgG, IgM and IgA isotypes
with the predominance of IgG (Lacroix-Desmazes et al.
1995).
The presence of anti-HSP 60 antibodies, as a part of
natural human immune repertoire, has been confirmed in
different other disorders, as well as in healthy subjects
(Varbiro et al. 2010; Lacroix-Desmazes et al. 1995; Zlacka
et al. 2006).
Although natural autoantibodies levels against different
conserved proteins remain stable with time, large inter-
individual differences may be observed (Mouthon et al.
1996), nevertheless, the autoreactive repertoires are highly
conserved among individuals (Varbiro et al. 2010;
Table 2 Biochemical data of
the study population
Biochemical data Alzheimer’s disease







mean ± SD (range)
2.86 ± 0.94 (1.07–4.95) 1.10 ± 0.73 (0.15–3.3) p\ 0.05
IgM titer (MU/mL),
mean ± SD (range)
11.83 ± 2.31 (7.59–16.99) 6.14 ± 1.49 (4.2–9.4) p\ 0.05
Anti-HSP60 antibodies
IgG titer (MU/mL),
mean ± SD (range)
1.95 ± 0.76 (0.69–3.67) 1.79 ± 0.88 (0.76–5.82) p = 0.29
Data are presented as means with standard deviation (SD) and range. p\ 0.05, significant difference in
comparison to control
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Mouthon et al. 1995). This unique reactivity pattern very
characteristic of each individual is described as an ‘‘anti-
body immuno-fingerprinting’’. Our results are in accor-
dance with data from previously performed studies, as we
also observed large variability of anti-HSP60 IgG anti-
bodies titers, which is presented in Fig. 1.
Of course, we cannot exclude the influence of factors
other than chronic neurodegenerative process on the pres-
ence of discussed immune response against HSP60. HSP
are considered one of the superantigens and are the
immunodominant antigens of various microbial pathogens
inducing strong humoral and cellular immune responses in
numerous infections caused by bacteria, protozoa, fungi
and nematodes (Shinnick 1991; Kaufmann and Schoel
1994). Recent data suggest that particularly the viral
infections may influence the activity of sHSP and subse-
quent autoimmunity (Temajo and Howard 2004; Rajaiah
and Moudgil 2009).
Based on results of our study, we admit that anti-HSP60
antibodies may belong to natural autoantibodies repertoire,
Table 3 Demographic clinical and biochemical characteristic of subgroups of Alzheimer’s disease patients
Subgroups of AD patients Mild AD (A) Moderate AD (B) Severe AD (C)
CDR CDR 0.5–1.0 CDR 2.0 CDR 3.0
Patients number 19 22 18
Age (mean ± SD) (range) 69.42 ± 8.61 (55–83) 74.05 ± 6.63 (56–81) 75.28 ± 5.56 (68–84)
Mean MMSE (mean ± SD) (range) 21.58 ± 1.64 (20–24) 17.64 ± 1.09 (16–19) 10.94 ± 0.73 (9–12)
Disease duration (mean ± SD) 
(range)
1.87 ± 0.72 (1–3) 4.23 ± 0.67 (3–5) 6.61 ± 0.98 (5–8)
Anti-HSP60 ABs (mean ± SD) 
(range)
2.01 ± 0.67 (1.23–3.45) 1.69 ± 0.64 (0.72–
3.46)
2.20 ± 0.92 (0.69–3.67)
Anti-alpha-B-crystallin Abs IgM 
(MU/mL) (mean ± SD) (range)
11.30 ± 2.13 (8.09–
15.87)
11.74 ± 2.35 (7.59–
16.99)
12.49 ± 2.4 (8.37–16.59)
Anti-alpha-B-crystallin Abs IgG 
(MU/mL) (mean ± SD) (range)











(A vs B) p>0.05
(B vs C) p>0.05












(A vs B) p>0.05
(B vs C) p>0.05












(A vs B) p>0.05
(B vs C) p>0.05
(A vs C) 0.03
Data are presented as means with standard deviation (SD)
CDR Clinical Dementia Rating Scale, MMSE mini mental state examination, AD Alzheimer’s disease, Abs antibodies
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and chronic neurodegenerative process probably has addi-
tional, but rather poor influence on activation of the
immune system against HSP60.
Conclusions
Anti-HSP60 antibodies present in AD patients may indeed
belong to natural human immune repertoire, and chronic
neurodegenerative process does not have significant
inducing effect on the systemic immunoreactivity against
HSP60.
Increased titers of IgM and IgG autoantibodies against
alpha B-crystallin in AD patients may reflect activation of
humoral immune response in the course of this chronic
disease, probably secondary to increased expression of this
heat-shock protein. It is still unclear whether the examined
autoantibodies are primary factors responsible for neu-
rodegeneration, secondary phenomenon which occurs in
response to widespread neurodegenerative process, or
belong to natural human immune repertoire, without
having any pathogenic role. Further prospective studies on
larger group of AD patients and measuring a change in
antibodies titers with disease progression are necessary to
assess the exact role of these antibodies in AD.
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